IDEAYA Biosciences Inc Forecast, price target & analysts
IDEAYA Biosciences Inc Target price 2025 - Analyst rating & recommendation
IDEAYA Biosciences Inc Classifications & Recommendation:
IDEAYA Biosciences Inc Price Target
| Target Price | $51.85 |
| Price | $20.24 |
| Potential |
156.16%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target IDEAYA Biosciences Inc 2026 .
The average IDEAYA Biosciences Inc target price is $51.85.
This is
156.16%
register free of charge
$63.00
211.26%
register free of charge
$27.00
33.40%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend IDEAYA Biosciences Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the IDEAYA Biosciences Inc stock has an average upside potential 2026 of
156.16%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 7.00 | 13.82 |
| 70.07% | 97.41% | |
| EBITDA Margin | -4,616.29% | -2,010.52% |
| 727.90% | 56.45% | |
| Net Margin | -4,152.00% | -1,891.66% |
| 472.82% | 54.44% |
13 Analysts have issued a sales forecast IDEAYA Biosciences Inc 2025 . The average IDEAYA Biosciences Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an IDEAYA Biosciences Inc EBITDA forecast 2025. The average IDEAYA Biosciences Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 IDEAYA Biosciences Inc Analysts have issued a net profit forecast 2025. The average IDEAYA Biosciences Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.36 | -3.02 |
| 71.43% | 10.12% | |
| P/E | negative | |
| EV/Sales | 80.66 |
5 Analysts have issued a IDEAYA Biosciences Inc forecast for earnings per share. The average IDEAYA Biosciences Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the IDEAYA Biosciences Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
IDEAYA Biosciences Inc...
Current IDEAYA Biosciences Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Stephens & Co. | Locked ➜ Locked | Locked | Feb 14 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Jan 15 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Jan 13 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Dec 17 2024 |
| Wedbush | Locked ➜ Locked | Locked | Dec 17 2024 |
| Stephens & Co. | Locked ➜ Locked | Locked | Nov 18 2024 |
| Leerink Partners | Locked ➜ Locked | Locked | Nov 05 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Stephens & Co.: Locked ➜ Locked
|
Feb 14 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Jan 15 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Jan 13 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Dec 17 2024 |
|
Locked
Wedbush: Locked ➜ Locked
|
Dec 17 2024 |
|
Locked
Stephens & Co.: Locked ➜ Locked
|
Nov 18 2024 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Nov 05 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
